The University of Colorado Cancer Center proposes to establish a Specialized Program in Research Excellence (SPORE) in Lung cancer to expand our understanding of the biology of lung cancer, to find new methods of diagnosis, prevention and treatment and to serve as a regional, national and international resource for the study of lung cancer. As a part of this SPORE application we will conduct interrelating research projects, 8 clinical trials and support the 5 cores, the career development of 4 young investigators and the recruitment of new investigators with special research capabilities. Our research studies will focus on abnormalities in growth factors pathways, changes in preneoplastic epithelium, and abnormalities in lung cancer cells. This will include the study of oncogenes and suppressor genes and methods to reverse abnormalities. We will define intermediate markers associated with premalignant lesions and whether these markers change in response to discontinuation of smoking, retinoic acid therapy or other chemopreventive measures. We will study agents which interfere with lung cancer signal transduction and determine whether these are safe and useful for the treatment or prevention of lung cancer. We will assess strategies to stop cigarette consumption with high risk patients and the effects this has on intermediate markers. We will establish new clinical protocols and conduct them alone or in collaboration with other institutions. We will establish two """"""""Banks"""""""" of tissues: 1) a premalignant bank to include sputum and bronchial biopsies, bronchial brushings, bronchial lavage and urine; 2) a malignant bank to include tumor tissue, adjacent lung serum, and lymphocytes. These tissues will be studied by our investigators and made available to the scientific community on a peer-reviewed/availability basis. We will collaborate with other lung cancer SPORES and lung cancer investigators to reach our goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058187-02
Application #
3105262
Study Section
Special Emphasis Panel (SRC (52))
Project Start
1992-09-30
Project End
1995-08-31
Budget Start
1993-09-30
Budget End
1994-08-31
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Iams, Wade T; Yu, Hui; Shyr, Yu et al. (2018) First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer 19:531-543
McDaniel, Nellie K; Cummings, Christopher T; Iida, Mari et al. (2018) MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Mol Cancer Ther 17:2297-2308
Ghosh, Moumita; Miller, York E; Vandivier, R William et al. (2018) Reply to Sohal: Airway Basal Cell Reprogramming and Epithelial-Mesenchymal Transition: A Potential Key to Understanding Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:1645-1646
Ghosh, Moumita; Miller, York E; Nakachi, Ichiro et al. (2018) Exhaustion of Airway Basal Progenitor Cells in Early and Established Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:885-896
Farago, Anna F; Taylor, Martin S; Doebele, Robert C et al. (2018) Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol 2018:
He, Yayi; Liu, Sangtian; Mattei, Jane et al. (2018) The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Des Devel Ther 12:981-986
Genova, Carlo; Socinski, Mark A; Hozak, Rebecca R et al. (2018) EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. J Thorac Oncol 13:228-236
Merrick, Daniel T; Edwards, Michael G; Franklin, Wilbur A et al. (2018) Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res 78:4971-4983
Li, Howard Y; McSharry, Maria; Walker, Deandra et al. (2018) Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II. Oncoimmunology 7:e1423182

Showing the most recent 10 out of 435 publications